research Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/– mice
Targeting ornithine decarboxylase can help prevent skin cancer.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch PROTACs in 2025: from the laboratory concept to clinical breakthrough
PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
research Exclamation marks and other trichoscopic signs of chemotherapy-induced alopecia
Chemotherapy can cause hair changes similar to alopecia areata, which might lead to misdiagnosis.
research A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata
Platelet-rich plasma treatment significantly increased hair regrowth and decreased discomfort in alopecia patients, making it a potentially better and safer treatment option.
research Vitiligo as a Reaction to Topical Treatment with Diphencyprone
Diphencyprone treatment for alopecia areata can cause vitiligo in some patients.
research Confocal microscopy can assess the efficacy of combined microneedling and skinbooster for striae rubrae
Microneedling combined with skinbooster effectively treats striae rubrae, with confocal microscopy confirming collagen changes.
research A Natural Inhibitor, 1′S-1′-Acetoxychavicol Acetate, Against Testosterone-Induced Alopecia via NADPH Oxidase Regulation
1′S-1′-Acetoxychavicol acetate may help treat hair loss by reducing oxidative stress.
research Intermolecular NH 2 -/Carboxyl-terminal Interactions in Androgen Receptor Dimerization Revealed by Mutations That Cause Androgen Insensitivity
Mutations at Val-889 and Arg-752 disrupt key interactions in androgen receptor dimerization.
research Colorimetric assay for γ-glutamyl transpeptidase
The document concludes that measuring γ-glutamyl transpeptidase activity is more accurate with a higher substrate concentration and using diluted acetic acid to stop the reaction.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.